Sunday , April 11 2021

Specialty Pharma Journal Specialty, Precision & Technology

Breaking News

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Tag Archives: Alimta

November, 2015

19 November
Lilly and Merck Expand Immuno-Oncology Collaboration with Late-Stage NSCLC Study

INDIANAPOLIS and KENILWORTH, N.J., Nov. 19, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) …
Share

April, 2015

2 April
OncoMed to Investigate the Combination of its Experimental Cancer Drug with Lilly’s Alimta in Lung Cancer

OncoMed Pharmaceuticals, Inc. has teamed up with Eli Lilly and Company to test a combination of the companies’ drugs for treatment of lung cancer. The companies announced that they have entered into an agreement, under which OncoMed’s anti-DLL4 antibody, demcizumab, is being tested in combination with Lilly’s lung cancer drug, …
Share